HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Heron Therapeutics in a research note issued to investors on Thursday, February 26th. HC Wainwright analyst B. Folkes now anticipates that the biotechnology company will earn ($0.06) per share for the year, down from their previous forecast of ($0.05). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

A number of other analysts also recently weighed in on HRTX. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Finally, Zacks Research cut Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Price Performance

HRTX stock opened at $1.19 on Monday. The company has a market capitalization of $224.36 million, a P/E ratio of -9.15 and a beta of 1.26. The company has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.27. The company has a debt-to-equity ratio of 10.59, a quick ratio of 1.51 and a current ratio of 2.48. Heron Therapeutics has a 52-week low of $1.00 and a 52-week high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business had revenue of $40.59 million for the quarter, compared to analyst estimates of $39.53 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. PKS Advisory Services LLC acquired a new stake in Heron Therapeutics during the third quarter worth approximately $25,000. Advisory Services Network LLC lifted its stake in Heron Therapeutics by 2,383.4% in the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 18,114 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics during the 2nd quarter worth approximately $26,000. Jones Financial Companies Lllp grew its position in shares of Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after buying an additional 23,661 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Heron Therapeutics by 39.1% in the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 6,858 shares in the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Key Heron Therapeutics News

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results and company guidance: Heron reported Q4 revenue of $40.59M and EPS of ($0.02), both modest beats vs. Street estimates, and reported full‑year 2025 net revenue of $154.9M (65% YoY growth driven by ZYNRELEF and APONVIE). Management issued FY2026 net revenue guidance of $173–$183M and adjusted EBITDA guidance of $10–$20M — a clear near‑term commercial growth signal. Heron Press Release
• Positive Sentiment: HC Wainwright reiterates Buy and $6 target: Analyst B. Folkes continues to rate HRTX a Buy and models a multi‑year recovery to profitability (FY2027+), including an eventual FY2030 EPS of $0.55 — signaling meaningful upside from current levels if execution and product growth continue. (HC Wainwright research note)
• Neutral Sentiment: HC Wainwright near‑term modeling: The firm provided detailed Q1–Q4 2026 EPS estimates (Q1 -$0.03, Q2 -$0.02, Q3 -$0.01, Q4 $0.00) and a FY2026 consensus around -$0.13 — useful visibility but not an immediate catalyst. (HC Wainwright research note)
• Neutral Sentiment: Coverage and takeaways from the quarter are circulating: earnings call highlights and analyst write‑ups summarize the beat, commercial momentum, and guidance. These pieces help investors parse the quarter but largely echo the company release. Earnings Call Highlights Zacks Analysis WTOP Snapshot
• Negative Sentiment: Modest medium‑term EPS downgrades from HC Wainwright: The analyst trimmed FY2027, FY2028 and FY2029 EPS forecasts slightly (FY2027 to $0.14 from $0.15; FY2028 to $0.39 from $0.43; FY2029 to $0.44 from $0.48). Those cuts reduce some of the upside implied by prior estimates and may have tempered enthusiasm after recent share gains. (HC Wainwright research note)

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.